Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR52 | Q9Y2T5 | 3/20 | 0.50 |
| ▸ | SLC9A1 | P19634 | 3/20 | 0.48 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.47 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.41 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | RXRB | P28702 | 1/20 | 0.40 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.39 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.39 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1851699 | 0.90 | GPR52 (0.52) | GPR52SLC9A1S1PR5PLA2G2APTGER1 | |
| SCHEMBL1851841 | 0.86 | GPR52 (0.48) | GPR52SLC9A1S1PR5 | |
| SCHEMBL1849212 | 0.85 | GPR52 (0.53) | GPR52SLC9A1S1PR5PTGER1CYP2C9 | |
| SCHEMBL1852836 | 0.85 | GPR52 (0.58) | GPR52SLC9A1S1PR5S1PR4 | |
| SCHEMBL1852762 | 0.84 | GPR52 (0.54) | GPR52S1PR5PLA2G2APTGER1CYP2C9 | |
| SCHEMBL1851749 | 0.83 | GPR52 (0.60) | GPR52SLC9A1 | |
| SCHEMBL3208649 | 0.83 | GPR52 (0.57) | GPR52SLC9A1S1PR5 | |
| SCHEMBL1850164 | 0.81 | GPR52 (0.52) | GPR52PLA2G2APTGER1CYP2C9RXRA | |
| SCHEMBL3223348 | 0.81 | GPR52 (0.52) | GPR52SLC9A1S1PR5PLA2G2AS1PR4 | |
| SCHEMBL1852510 | 0.80 | GPR52 (0.57) | GPR52SLC9A1S1PR5PLA2G2AS1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2323978-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010018874-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | WO | disclosed |
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041891-A1 | AMIDE COMPOUND | GPR52, GPR132, NR5A2 | GPR52 1/4885SLC9A1 1722/4885S1PR5 696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.